PHILADELPHIA, June 25, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that Steven Kelly, President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2024 Cell Therapy Forum on Tuesday, July 9th at 9:10 am ET. About Carisma Investors: Shveta Dighe Head of Investor Relations [email protected] SOURCE Carisma Therap ...

Meeting will be reconvened on Friday, June 14, 2024 at 10:00 a.m. Eastern Time Carisma stockholders will be able to attend the virtual annual meeting online, vote their shares electronically and submit questions via the Internet by virtual audio web conference at https://meetnow.global/MAJJ4AY. Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer ...

CT-0525 is the first CAR-Monocyte to be evaluated in humans in the solid tumor setting Initial data expected by year-end 2024 PHILADELPHIA, May 16, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the first patient was dosed in its Phase 1 clinical trial evaluating CT- 0525, an ex vivo gene-modified autologous chimeric antigen receptor-m ...

Carisma Therapeutics Inc. (CARM) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $1.93 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -24.32%. A quarter ago, it was expected that this company would post a loss of $0.56 per share when it actually produced a loss of $0.52, delivering a surprise of 7.14%.Over the last four quarters, the company ha ...

See accompanying notes to unaudited interim consolidated financial statements. CARISMA THERAPEUTICS INC. Notes to the Interim Consolidated Financial Statements In late March 2024, the Company and its board of directors approved a revised operating plan to reduce monthly operating expenses and conserve cash to begin implementation in April 2024. The plan, includes several measures such as, including prioritizing CT0525, the Company's second product, as its lead anti-human epidermal growth factor receptor 2 ( ...

Exhibit 99.1 Announced CT-0525 as lead product candidate for anti-HER2 program; initial data expected by year-end 2024 Presented Regimen Level 1 data from Phase 1 sub-study utilizing CT-0508 in combination with pembrolizumab at AACR; expects to report Regimen Level 2 data in second quarter of 2024 First Quarter 2024 Highlights and Upcoming Milestones · CT-0508 (Anti-HER2 CAR-Macrophage) o In late March 2024, Carisma made the decision to pause further development of CT-1119, pending additional financing. o O ...

Announced CT-0525 as lead product candidate for anti-HER2 program; initial data expected by year-end 2024 Presented preclinical proof of concept data in liver fibrosis at ASGCT; expects to nominate a development candidate in the first quarter of 2025 Presented Regimen Level 1 data from Phase 1 sub-study utilizing CT-0508 in combination with pembrolizumab at AACR; expects to report Regimen Level 2 data in second quarter of 2024 Cash and cash equivalents of $56.5 million expected to fund the Company into the ...

Novel anti-fibrotic engineered macrophage therapy reduced liver fibrosis in preclinical models Development candidate nomination expected in the first quarter of 2025 PHILADELPHIA, May 8, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced new data demonstrating preclinical proof of concept using engineered anti-fibrotic macrophages for the treat ...

Industry veteran with expertise in oncology and immuno-oncology and a strong track record of advancing programs through clinical development PHILADELPHIA, May 2, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Eugene P. Kennedy, M.D., F.A.C.S. as the Company's Chief Medical Officer. Dr. Kennedy brings over 15 years of cli ...

PHILADELPHIA, April 24, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced its upcoming presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting taking place from May 31- June 4, 2024, in Chicago, IL. Details on the poster presentation at ASCO 2024 are below: Poster Title: A phase 1, first-in-human study of autologou ...